BioCareSD Announces Limited Distribution Partnership with GCBioPharma for ALYGLO®
This partnership underscores BioCareSD’s commitment to delivering vital therapies through its high-touch service model, which ensures that customers receive the personalized support they need to focus on patient outcomes.
“We are thrilled to partner with GCBioPharma as a Limited Distributor for ALYGLO®,” said Jeff Beck, Chief Development Officer with BioCareSD. “Our goal is to provide exceptional service that allows our customers to concentrate on what matters most—improving patient outcomes. This collaboration reflects our dedication to supporting patients with rare and complex conditions through our comprehensive distribution network.”
FDA-approved ALYGLO®, treats patients with primary humoral immunodeficiency (PI), a group of disorders characterized by an impaired ability to produce antibodies. Patients with this rare disease are more susceptible to infection such as bacterial infections affecting the gastrointestinal and respiratory tracts. ALYGLO® works to treat PI by boosting the immune system.
About BioCareSD
BioCareSD, a BioCare company, has been providing patients across the country with fast and easy access to life-saving medications for over 40 years. This is accomplished via their wide-reaching nationwide network of distribution centers and agile distribution capabilities, offering both STAT and emergency deliveries. Headquartered in Tempe, Arizona, BioCareSD has a central customer support team and local, field-based account management teams, available 24 hours a day, 7 days a week, 365 days a year. For more information, please visit www.biocare-us.com.
For media inquiries please contact Kristen Peifer at kristen@maroonpr.com
Kristen Peifer
Maroon PR
kristen@maroonpr.com
Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry, Science
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release